International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
By D. Farge, P. Debourdeau, M. Beckers, C. Baglin, R. Bauersachs, B. Brenner, D. Brilhante, A. Falanga, G. Gerotzafias, N. Haim and 16 more. Journal of Thrombosis and Haemostasis, 2013
711 citations recorded by the source corpus.
Subfields: Emergency Medical Services, Internal Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/fcc8d8dc061e3a423ca8086809a2ea4f723cd094
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Internal Medicine
Citations in the corpus
- 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines (2016, background): “Recurrent VTE may still occur despite VKA or LMWH therapy in patients with cancer, and may be managed by switching from VKA to LMWH or increasing the LMWH dose.(191) A vena cava filter, either definitive or retractable, may be implanted when anticoagulation is contraindicated or failing.”
- ESC Guidelines on the diagnosis and management of acute pulmonary embolism (2014, background): “Therefore, the search for occult cancer after an episode of VTE may be restricted to careful history, physical examination, basic laboratory tests, and a chest X-ray.(461,462)”
- [2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism]. (2014, neutral): “Therefore, the search for occult cancer after an episode of VTE may be restricted to careful history, physical examination, basic laboratory tests, and a chest X-ray.(461,462)”
- 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). (2016, background): “Recurrent VTE may still occur despite VKA or LMWH therapy in patients with cancer, and may be managed by switching from VKA to LMWH or increasing the LMWH dose.(191) A vena cava filter, either definitive or retractable, may be implanted when anticoagulation is contraindicated or failing.”
- Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. (2012, background): “There is new moderate quality evidence that CDT can reduce PTS of the leg90 (Table 14, e-Table 15) and that systemic thrombolysis increases bleeding in patients with acute PE,143,147 and low-quality evidence that CDT can accelerate breakdown of acute PE.154 This evidence has indirect bearing on thro”